ANDS
ANDS (1-Amino-8-naphthol-2,4-disulfonic acid) is an orally active inhibitor of CaMKP (IC50 = 6.4 μM; Ki = 3.6 μM) and CaMKP‑N (IC50 = 6.6 μM). ANDS binds unacetylated p53 and restores p53 activity by disrupting ANP32B-p53 interaction. ANDS inhibits chronic myeloid leukemia (CML) cell proliferation, impairs leukemic stem cells (LSC) function and prolongs survival in CML mouse model while sparing normal progenitor cells. ANDS can be used to study the eradication of LSCs and the overcoming of tyrosine kinase inhibitor (TKI) resistance in CML. ANDS can be used to study breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 16781-09-2
- Formel: C10H7NNa2O7S2
- Molecular Weight:363.27
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CaMKP 6.4 μM (IC50) |
CaMKP 3.6 μM (Ki) |
CaMKP-N 6.6 μM (IC50) |
In Vitro
ANDS (compound 5) (5-40 μM; 4 h) inhibits in vitro ANP32B-p53 interaction in a dose-dependent manner[1].
ANDS (5-100 μM; 1 h) inhibits ANP32B-p53 interaction, enhances p53 thermal stability without affecting ANP32B at 5 μM, induces concentration-dependent p53 stabilization at 48°C, and directly targets p53 in KU812 cells in lysate-based CETSA experiments[1].
ANDS (10 μM; 4 h) specifically precipitates GST-tagged p53-CTD, but not ANP32B, in streptavidin pull-down assays, a finding confirmed in KU812 cells, while biotin-conjugated compound retains its ability to disrupt the ANP32B-p53 interaction[1].
ANDS (5 μM) directly binds to immobilized p53‑CTD (KD = 1.496 μM) and, when pre‑incubated with p53‑CTD at 5 μM, weakens the ANP32B‑LCAR/p53‑CTD interaction (KD increased to 18.59 μM)[1].
ANDS (0-80 μM) inhibits the ANP32B-LCAR/p53-CTD interaction in a dose-dependent manner, with an IC50 of 4.5682 μM[1].
ANDS (250 μM) binding induces extensive conformational rearrangements of p53-CTD and precludes its association with ANP32B[1].
ANDS (0-20 μM; 48 h) reduces the viability of KU812 and K562‑p53 cells in a dose‑dependent manner, with IC50 values of 4.637 μM and 5.654 μM[1].
ANDS (1-50 μM; 48 h) nearly abolishes ANP32B-p53 binding and promotes p53 acetylation at 5 μM in KU812 and K562-p53 cells, while 50 μM is needed to disrupt SET/TAF1β-p53 interaction in KU812 cells, demonstrating greater selectivity for ANP32B-p53[1].
ANDS (5 μM; 48 h) significantly enhances p53 acetylation and transcriptional activity in the presence of ANP32B, similar to the effect of ANP32B ablation alone in KU812 cells[1].
ANDS (5 μM; 4 h) specifically pulls down unacetylated p53 (p53WT and p53KR, but not p53KQ) in K562 cells in streptavidin pull-down assays[1].
ANDS (5 μM; 48 h) competitively prevents the interaction between ANP32B and unacetylated p53, leading to increased p53 acetylation, while showing no significant effect on the SET/TAF1β-p53 complex at this concentration in KU812 and K562-p53 cells[1].
ANDS (5 μM; 48 h) enhances p53 transcriptional activity in K562-p53WT and K562-p53KR cells, but not in K562-p53KQ cells[1].
ANDS (5 μM; 48 h) treatment does not alter ANP32B phosphorylation status or its nuclear localization but specifically disrupted the ANP32B-p53 interaction in the nuclei in KU812 cells[1].
ANDS (5 μM; 2-10 days) inhibits proliferation and promotes apoptosis at 5 μM in ANP32B-wildtype KU812 and K562-p53 cells, whereas ANP32B knockdown in KU812 cells partially reverses these effects[1].
ANDS (5 μM) inhibits the CML cell line proliferation by specifically disrupting the direct interaction between ANP32B and p53[1].
ANDS (0-20 μM; 2-7 days) dose-dependently inhibits growth and colony formation and induces apoptosis in Anp32b+/+ CML cells, but promotes growth and inhibits apoptosis in Anp32b–/– CML cells[1].
ANDS (5-20 μM; 6-48 h) dose- and time-dependently upregulates p-CaMKIIγ levels in both KU812 and K562-p53 cells[1].
ANDS (5 μM; 1-10 days) combined with KN93 (HY-15465) synergistically inhibits growth and promotes apoptosis in ANP32B-proficient KU812 cells, but shows no synergy in ANP32B-deficient KU812 cells, where KN93 only blocks ANDS-induced p-CaMKIIγ upregulation without reversing ANDS-promoted growth and apoptosis inhibition; similar results are obtained in K562-p53 cells[1].
ANDS (5 μM) disrupts ANP32B-p53 binding, inhibits cell growth, and promotes apoptosis in TKI‑resistant KBM5‑T315I cells, with these effects being more pronounced when combined with KN93[1].
ANDS (5 μM; 10 days) combined with KN93 exerts synergistic therapeutic efficacy in all three cases of human CML samples[1].
ANDS (compound 5) (0-10 μM) exhibits potent inhibitory activity against CaMKP and CaMKP-N, with IC50 values of 6.4 μM and 6.6 μM, respectively, and a Ki value of 3.6 μM toward CaMKP, while showing no significant inhibition against PP2C or CaN under the same conditions[2].
ANDS (10 μM; 4 min) can inhibit dephosphorylation of phosphoprotein substrates by CaMKP, as in the case of phosphopeptide substrates[2].
ANDS (10 μM; 6 h) can be effectively incorporated into cells to inhibit CaMKP-N expressed in Neuro2a cells[2].
ANDS (0-30 μM; 22 h) causes a marked reduction in cell migration without significant cytotoxicity, again suggesting that the phosphatase activity of CaMKP is crucial for the regulation of cancer cell motility in MDA-MB-231 cells[3].
ANDS (30 μM; 24 h) is able to inhibit the cellular CaMKP activity in MDA-MB-231 cells, thereby inhibiting the cell migration[3].
ANDS (30 μM) does not inhibit the phosphatase activity of hCaMKP-N(1–559) even at 30 μM, a concentration at which the rat CaMKP was strongly inhibited[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
ANDS (10 mg/kg; i.g.; twice a day; 30 days) suppresses Anp32b⁺/⁺ CML and LSCs while accelerating Anp32b⁻/⁻ CML in both primary and secondary transplanted mice, indicating that ANDS impairs LSC function via ANP32B-p53 disruption but also exerts ANP32B-independent effects[1].
ANDS (10 mg/kg; i.g.; twice a day; 8 days) synergizes with KN93 to suppress CML progression through p‑CaMKIIγ inhibition in Bcr‑AblWT‑induced CML mouse models[1].
ANDS (10 mg/kg; i.g.; twice a day; 8 days) combined with KN93 synergistically suppresses Anp32b⁺/⁺ CML progression in Bcr‑AblWT‑induced CML mouse models, but exhibits no such synergy in Anp32b⁻/⁻ CML mice[1].
ANDS (10 mg/kg; i.g.; twice a day; 8 days) combined with KN93 synergistically suppresses the progression of both TKI-sensitive and -resistant CML in mouse models[1].
ANDS (10 mg/kg; i.g.; twice a day; 8 days) as a single agent is effective, and combined with KN93 exhibits a stronger effect in the Bcr‑AblT315I‑induced Imatinib (HY-15463) ‑resistant CML mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:10 mg/kg
-
Administration:i.g.; twice a day; 30 days
-
Result:Resulted in a slight decrease in the frequencies of Lin–Sca-1+c-Kit+ (LSK) cells, including LT-HSCs, ST-HSCs, and MPPs.
Don’t affect total bone marrow (BM) cell numbers, progenitor and mature cell populations.
Don’t cause significant alterations in body weight or the appearance of the livers, spleens, and lungs.
-
Animal Model:10-12-week-old donor mice are injected with 5‑fluorouracil (120 mg/kg) via tail vein; 6 days later, their Lin⁻ bone marrow cells are harvested, infected with Bcr‑AblWT or Bcr‑AblT315I‑IRES‑GFP virus, and then transplanted (5×10⁴ cells) into lethally irradiated (3+3 Gy) C57BL/6 recipients, from which GFP⁺ leukemic cells are subsequently isolated for secondary transplantation into new recipients[1].
-
Dosage:10 mg/kg
-
Administration:i.g.; twice a day; 8 days
-
Result:Showed that the two-agent combinations demonstrated greater efficacy compared to the single agents, while the three-agent combination exhibited the most potent effect.
Decreased counts of GFP+ CML cells in peripheral blood (PB) and BM, reduced GFP+LSK cells, and increased percentage of apoptotic GFP+LSK cells in BM, as well as reduced spleen size and weight and prolonged mouse survival.
Chemical Information
-
CAS. Nr. 16781-09-2
-
Molecular Weight 363.27
-
Formel C10H7NNa2O7S2
-
SMILES
NC1=C(C=C(C2=C1C(O)=CC=C2)S(=O)(O[Na])=O)S(=O)(O[Na])=O
-
Synonyms
1-Amino-8-naphthol-2,4-disulfonic acid
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Reinheit & Dokumentation
Verweise
[1]. Wei YS, et al. The disulfonic acid ANDS disrupts ANP32B-p53 interaction to suppress chronic myeloid leukemia. Nat Commun. 2026 Jun 10. [Content Brief]
[2]. Sueyoshi N, et al. Inhibitors of the Ca(2+)/calmodulin-dependent protein kinase phosphatase family (CaMKP and CaMKP-N). Biochem Biophys Res Commun. 2007 Nov 23;363(3):715-21. [Content Brief]
[3]. Akizuki K, et al. CaMK phosphatase (CaMKP/POPX2/PPM1F) inhibitors suppress the migration of human breast cancer MDA-MB-231 cells with loss of polarized morphology. Biochem Biophys Res Commun. 2023 Jan 8;639:1-8. [Content Brief]
[4]. Ishida A, et al. An active C-terminally truncated form of Ca (2+) /calmodulin-dependent protein kinase phosphatase-N (CaMKP-N/PPM1E). Biomed Res Int. 2013;2013:134813. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)